Renascience Inc.
Stock Price Chart
2026/07/21 UpdatedPrice Trend
2026/07/21 UpdatedPrice & Trading Details
2026/07/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/07/01Financial Performance
2026/07/19 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥101M | ¥194M | ¥133M | ¥69M |
| Gross Profit | ¥100M | ¥166M | ¥129M | ¥64M |
| Operating Income | -¥334M | -¥252M | -¥179M | -¥357M |
| Pretax Income | -¥334M | -¥252M | -¥179M | -¥357M |
| Net Income | -¥336M | -¥258M | ¥113M | -¥301M |
| EPS | -¥26.42 | -¥20.32 | ¥8.92 | - |
| Operating Margin | -332.06% | -129.96% | -134.77% | -520.59% |
| Balance Sheet | ||||
| Total Assets | ¥2,275M | ¥2,089M | ¥1,871M | ¥3,503M |
| Total Equity | ¥1,865M | ¥1,607M | ¥1,720M | ¥3,323M |
| Total Liabilities | ¥410M | ¥482M | ¥151M | ¥181M |
| Cash | ¥2,212M | ¥2,027M | ¥1,800M | ¥3,403M |
| Interest-bearing Debt | ¥310M | ¥356M | ¥0M | - |
| Equity Ratio | 81.99% | 76.92% | 91.92% | 94.85% |
| D/E Ratio | 0.17 | 0.22 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥285M | -¥231M | -¥176M | -¥291M |
| Investing CF | ¥0M | -¥2M | ¥382M | - |
| Financing CF | ¥110M | ¥47M | -¥52M | ¥1,894M |
| Free CF | -¥287M | -¥232M | -¥177M | -¥291M |
| Efficiency | ||||
| ROE | -18.00% | -16.08% | 6.59% | -9.07% |
| ROA | -14.76% | -12.37% | 6.06% | -8.60% |
Latest IR Information
-
Announcement of Clinical Trial Initiation in Saudi Arabia | July 2026
Lenascience Inc. has initiated Phase I clinical trials in collaboration with KAIMRC in Saudi Arabia, scheduled to be completed by the end of December 2026. The clinical trial evaluates the safety and tolerability of RS5614, with plans to proceed to...
Read more -
Initiation of Localized Advanced Non-Small Cell Lung Cancer Clinical Trial | July 2026
Lenasience commenced a Phase II clinical trial for localized advanced non-small cell lung cancer on July 16, 2026, assessing the efficacy and safety in 27 cases. The trial is scheduled from April 2026 to March 2029.
Read more -
【Renasa Science】 Progress in Obesity and Lifestyle Disease-Related Research｜July 2026
Renasa Science discloses research results related to obesity to investors, explaining the roles of plasma PAI-1 and the obesity-suppressing effects of P1 inhibitors.
Read more -
Frequently Asked Questions and Responses
Demonstrates medium- to long-term strategies prioritizing drug approval and上市 in the oncology field. The scheduled completion date for Phase III trials is September of this year, with results expected within this period. The company is negotiating license and sales partnerships...
Read more
Latest News (5 items)
Company Information
About
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Sendai, Japan.
